Alpha1H before surgery for low-risk bladder cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a new medicine called Alpha1H that is given before the usual surgery to remove bladder cancer. It may help lower the risk of the cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a low- or intermediate-risk type of bladder cancer that has not spread into the bladder muscle (non-muscle invasive).
- Your tumor(s) must be small (0.5 cm to 3 cm) and low-grade (not aggressive).
- You must be able to hold urine in your bladder for 2 hours.
- You must not have had previous BCG treatment for bladder cancer.
- You must not have had other cancer (except certain skin cancers) within the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving mitomycin directly into the bladder before surgery can help people with high-risk non-muscle-invasive bladder cancer. The goal is to see if this approach is safe and effective at preventing cancer from coming back.
This study compares two standard treatments for high-grade non-muscle-invasive bladder cancer that has come back after initial treatment: medication placed directly into the bladder (intravesical therapy) or bladder removal surgery (cystectomy). The goal is to see which option works better for patients like you.
This clinical trial tests a new drug, BH011, for people with high-risk, non-muscle-invasive bladder cancer that has come back or not responded to BCG therapy. The goal is to see if the drug is safe and works well when given directly into the bladder, as an alternative to bladder removal surgery.
This trial tests STM-416, given around the time you have surgery to remove recurring bladder tumors, to see if it can reduce the chance the cancer comes back. It is for people with high-risk early bladder cancer (non–muscle-invasive) who have already had standard treatment and now need another TURBT.
This study tests a new way to give a chemotherapy drug during bladder surgery to help stop the cancer from returning. It is for people with a type of bladder cancer that has not spread into the muscle.
This trial tests whether the drug bicalutamide can help men with early-stage (non-invasive) bladder cancer, which has not grown into the bladder muscle. It is given before surgery to see if it can reduce the chance of the cancer coming back. Participants will be randomly assigned to receive bicalutamide or a placebo before their scheduled surgery.
Hear when a new Urinary Bladder Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.